Core Viewpoint - The performance of fund managers is crucial for investors, especially for actively managed funds, and the article highlights the top-performing fund managers in the first half of 2025 based on their returns and management scale [2][34]. Group 1: Overall Fund Manager Performance - A total of 3,358 fund managers reported their performance for the first half of 2025, with an average return of 4.89% and a median return of 0.93% [2]. - Larger fund managers tend to have lower overall returns, possibly due to a lack of index-driven market trends and a higher proportion of managers handling bond and money market funds [2][34]. Group 2: Fund Managers with Over 100 Billion Yuan - Among fund managers managing over 100 billion yuan, the average return was 2.50% with a median of 0.93%, and the threshold for the top 20 was approximately 15.60% [3][4]. - The top five fund managers in this category are: 1. Wu Yuanyi (Guangfa Fund) - 32.19% return 2. Yan Siqian (Penghua Fund) - 24.65% return 3. Zhao Bei (ICBC Credit Suisse Fund) - 23.32% return 4. Yang Dong (Guangfa Fund) - 22.50% return 5. He Qi (Huatai-PB Fund) - 20.50% return [4][5]. Group 3: Fund Managers with 50-100 Billion Yuan - For fund managers managing between 50-100 billion yuan, the average return was 4.41% with a median of 1.87%, and the threshold for the top 20 was nearly 14% [11][12]. - The top five fund managers in this category are: 1. Zheng Ning (Bank of China Fund) - 58.14% return 2. Zhang Wei (Huitianfu Fund) - 42.36% return 3. Yang Zhenshao (E Fund) - 40.25% return 4. Zhao Wei (Fortune Fund) - 36.83% return 5. Nong Bingli (Invesco Great Wall Fund) - 33.00% return [12][16]. Group 4: Fund Managers with 20-50 Billion Yuan - Fund managers in the 20-50 billion yuan range had an average return of 5.31% and a median of 3.04%, with a top 20 threshold of about 21% [19][20]. - The top five fund managers in this category are: 1. Zhou Sicong (Ping An Fund) - 57.27% return 2. Peng Chenchen (Fortune Fund) - 40.22% return 3. Jin Xiaofei (Penghua Fund) - 39.85% return 4. Sang Xiangyu (Huashan Fund) - 38.69% return 5. Hao Miao (Jia Shi Fund) - 33.12% return [20][22]. Group 5: Fund Managers with 5-20 Billion Yuan - For fund managers managing between 5-20 billion yuan, the average return was 5.93% with a median of 4.03%, and the threshold for the top 20 was approximately 24.56% [23][24]. - The top five fund managers in this category are: 1. Zhang Jintao (Huabao Fund) - 41.93% return 2. Zhao Xiaoyan (Hengyue Fund) - 39.10% return 3. Chi Chenshen (Anxin Fund) - 36.26% return 4. Shan Lin (Yongying Fund) - 36.13% return 5. Zhang Jialu (Ruiyuan Fund) - 33.15% return [24][28].

Group 1 - The innovative drug sector is experiencing significant growth, with multiple stocks seeing substantial increases, including a more than 15% rise in Hotgen Biotech's stock price, reaching a historical high [1] - The National Healthcare Security Administration (NHSA) has issued a milestone document, the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," which opens new payment channels for innovative drug development [1] - Recent measures from the NHSA and the National Health Commission support the innovative drug industry by enhancing R&D support, promoting the inclusion of innovative drugs in the medical insurance directory, and facilitating clinical applications [1] Group 2 - Medical institutions are prohibited from limiting the use of innovative drugs based on the number of drugs in the directory or drug cost ratios, removing barriers to clinical application [2] - Hotgen Biotech is involved in both in vitro diagnostics and innovative drug development, with its global first heart attack antibody drug currently in clinical research in China and the U.S. [2] - The Hong Kong market's innovative drug sector is also active, with companies like Basilea Pharmaceutica and CanSino Biologics showing significant stock price increases, reflecting optimistic investor sentiment towards the innovative drug outlook [2]

Core Viewpoint - The Hong Kong IPO market has been thriving since 2025, with over 40 companies listed and total financing exceeding HKD 100 billion, indicating a significant increase in both the quantity and quality of cornerstone investors compared to the same period in 2024 [1][4]. Group 1: Cornerstone Investors - The number of cornerstone investors participating in Hong Kong IPOs has surged, with 189 cornerstone investors involved in 43 companies in the first half of 2025, averaging 4.39 investors per company, compared to 41 investors for 30 companies in the same period last year [4]. - The presence of high-quality cornerstone investors enhances the performance of newly listed stocks, as seen with companies like Ying'en Biotechnology-B, which had a first-day increase of 116.70% backed by 15 cornerstone investors [5]. Group 2: Local State-Owned Enterprises - Local state-owned enterprises (SOEs) have increasingly become key players in the cornerstone investment landscape, often linked to the companies' headquarters or significant local projects [7]. - The involvement of local government-backed funds as cornerstone investors significantly increases the likelihood of successful IPOs, as these investments align with local industrial development plans [8]. Group 3: Foreign Institutional Participation - The participation of well-known foreign institutions in cornerstone investments has risen, with a noticeable preference for large IPO projects, indicating a shift in foreign investment sentiment towards Chinese assets [10][11]. - Foreign investors are particularly interested in technology, pharmaceutical, and new consumer companies, reflecting a broader trend of international capital returning to the Hong Kong market [11][12].

Market Overview - The Hang Seng Index closed down 0.64% after failing to hold above 24,000 points, despite a temporary boost from financial stocks [1] - U.S. non-farm payrolls increased by 147,000 in June, exceeding expectations of 106,000, leading to a withdrawal of bets on a July interest rate cut by the Federal Reserve [1] - The U.S. government is expected to increase borrowing to offset tax cuts, with corporate tax rates potentially reduced from 21% to around 15% [1] - Market focus is on upcoming tariff deadlines, with President Trump indicating that tariff letters may be sent to trade partners soon [1] Geopolitical Tensions - The conflict between Russia and Ukraine has escalated, with Russia increasing its offensive due to the U.S. reluctance to provide large-scale weaponry to Ukraine [2] Banking Sector - Large funds are consolidating in banks, with Hong Kong's Liyue Group acquiring approximately 199 million shares of Minsheng Bank, raising its stake to 4.945% [3] - Insurance companies are also increasing their stakes in banks, with Ping An Life raising its holdings in China Merchants Bank to 15% [3] - Other banks like Harbin Bank and Zhengzhou Bank are also showing strong trends, with potential for mergers or acquisitions [3] Innovative Pharmaceuticals - Foreign investment in innovative pharmaceuticals is increasing, with Barclays being the largest holder of a new ETF focused on innovative drugs [4] - Companies like Kangfang Biotech and WuXi AppTec have seen significant stock price increases, reflecting strong market confidence in the CXO sector [4] - The Chinese government is taking serious measures to regulate the photovoltaic industry, with potential penalties for below-cost sales [4] Medical Devices and E-commerce - The National Medical Products Administration of China announced support for high-end medical devices based on brain-computer interface technology [5] - Jitu Express has seen a stock price increase due to strong growth projections from TikTok Shop in Southeast Asia [6] Automotive Sector - XPeng Motors launched its new SUV, the XPeng G7, with a lower starting price and immediate availability, although its stock fell by over 6% [6] Alibaba Group - Alibaba announced plans to issue zero-coupon exchangeable bonds worth approximately HKD 12 billion, with a potential impact on its stake in Alibaba Health [6] Fund Distribution in Hong Kong - The Hong Kong Stock Exchange announced the first batch of distributors for its integrated fund platform, which includes 12 Chinese brokers [7] Biopharmaceutical Company Performance - China Biopharmaceutical's new product, a recombinant coagulation factor VIIa, has received approval, contributing to a projected revenue of CNY 28.87 billion and a net profit of CNY 3.5 billion in 2024 [8] - The company is expected to continue its growth trajectory with a strong pipeline of innovative products and approvals [9]

Core Viewpoint - Multiple favorable policies have been released, leading to a collective surge in innovative drug stocks, with Kangfang Biotech's market capitalization surpassing HKD 100 billion [9][11]. Market Performance - On July 4, the Hang Seng Index initially dropped over 1.5% but later narrowed its losses, closing down 0.64% at 23,916.06 points, with a weekly decline of 1.52% [2]. - The total market turnover was HKD 267.8 billion, with southbound funds net buying HKD 6.68 billion [4]. - The healthcare sector index rose by 0.8%, while the materials sector index fell by nearly 1.2% [7]. Stock Highlights - Kangfang Biotech's stock price increased by 9.43% to HKD 116.10, with a total market value reaching HKD 104.2 billion [9][12]. - Other innovative drug companies also saw significant gains, including: - Boan Biotech up 8.55% - Cloudtop New Drug up 4.84% - WuXi AppTec up 4.31% [11][12]. Policy Impact - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, which are expected to expand market opportunities and encourage R&D efforts [12][13]. - The introduction of a commercial insurance innovative drug directory is seen as a significant exploration of an innovative payment system, injecting new vitality into the innovative drug ecosystem [13].

Core Viewpoint - Multiple favorable policies have been released, leading to a collective surge in innovative drug stocks, with Kangfang Biotech's market capitalization surpassing HKD 100 billion [9][14]. Market Performance - On July 4, the Hang Seng Index experienced a decline of 0.64%, closing at 23,916.06 points, with a weekly drop of 1.52% [1]. - The Hang Seng Biotechnology Index rose by 1.07%, indicating resilience in the biotech sector despite broader market declines [15]. - The total market turnover was HKD 267.8 billion, with net inflows from southbound funds amounting to HKD 6.68 billion [3]. Stock Performance - Notable gainers included: - Xinyi Solar, up 4.73% [4] - China Biologic Products, up 2.75% [4] - Hansoh Pharmaceutical, up 2.47% [4] - Kangfang Biotech's stock price increased by 9.43% to HKD 116.10, with a total market value reaching HKD 104.2 billion [10][13]. Policy Impact on Innovative Drugs - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, which positively impacted stock prices in the sector [17]. - The introduction of a commercial insurance directory for innovative drugs is expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [18]. Company Highlights - Kangfang Biotech's first dual-antibody ADC drug, AK146D1, has entered clinical trials, marking a significant milestone for the company [13]. - The company is recognized as the only global entity with two tumor immunotherapy dual antibodies, establishing a leading advantage in the IO+ADC landscape [13].

Core Insights - On July 4, 2025, Guotai Junan International (01788), Alibaba-W (09988), and SMIC (00981) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 10.714 billion, 3.571 billion, and 3.184 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Guotai Junan International (01788), Alibaba-W (09988), and Xiaomi Group-W (01810) also led the trading volume, with amounts of 3.641 billion, 3.489 billion, and 2.435 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 10.714 billion, net buy of 91.5226 million [2] - Alibaba-W (09988): 3.571 billion, net sell of 334 million [2] - SMIC (00981): 3.184 billion, net buy of 37.2 million [2] - Xiaomi Group-W (01810): 3.087 billion, net sell of 370 million [2] - Meituan-W (03690): 2.379 billion, net sell of 270 million [2] - China Construction Bank (00939): 2.120 billion, net buy of 168 million [2] - XPeng Inc. (09868): 2.108 billion, net buy of 919 million [2] - Tencent Holdings (00700): 1.900 billion, net sell of 145 million [2] - CanSino Biologics (09926): 1.674 billion, net sell of 95.5519 million [2] - Dmall (02586): 1.249 billion, net buy of 30.1596 million [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 3.641 billion, net buy of 50.5414 million [2] - Alibaba-W (09988): 3.489 billion, net sell of 1.153 billion [2] - Xiaomi Group-W (01810): 2.435 billion, net sell of 443 million [2] - SMIC (00981): 1.969 billion, net buy of 39.6 million [2] - Tencent Holdings (00700): 1.777 billion, net sell of 28.7313 million [2] - CanSino Biologics (09926): 1.675 billion, net buy of 19.5 million [2] - Meituan-W (03690): 1.660 billion, net buy of 96.5584 million [2] - XPeng Inc. (09868): 1.480 billion, net sell of 462.813 million [2] - Innovent Biologics (01801): 819 million, net buy of 18.2291 million [2] - China Mobile (00941): 622 million, net buy of 47.7507 million [2]

7月4日港股市场，北水成交净买入66.83亿港元，其中港股通(沪)成交净买入30.04亿港元，港股通(深)成 交净买入36.79亿港元。 港股通(深)活跃成交股 小鹏汽车-W(09868)获净买入8.72亿港元。消息面上，小鹏汽车公布，其全新中型SUV小鹏G7售价19.58 万元人民币起，远低于23.58万元的预售价，开售9分钟大定突破10,000辆。里昂认为，此次G7推出，象 征着集团已完成其SUV车型G6、G7及G9的矩阵，预计可带动全系列每月销售1.3万至1.7万辆。 中芯国际(00981)获净买入7.68亿港元。消息面上，西门子、新思科技和楷登电子公司发布的声明称，美 国政府已于本周四取消对中国部分芯片设计软件的出口管制措施。摩根士丹利5月发布的研究显示，三 家公司去年共占据中国EDA软件市场约82%的份额。EDA工具是芯片制造商在智能手机、计算机、汽车 等广泛应用领域中进行半导体设计的核心软件。 北水净买入最多的个股是小鹏汽车-W(09868)、中芯国际(00981)、建设银行（601939）(00939)。北水净 卖出最多的个股是阿里巴巴-W(09988)、小米集团-W(01810)、腾讯(007 ...

Group 1 - The Hong Kong IPO market is experiencing a "V-shaped rebound" with total fundraising reaching 140 billion HKD in the first half of 2023, a 7-fold increase compared to the same period in 2022 [3] - The average first-day gain for new listings is 15.2%, significantly higher than the 9.5% from the previous year [3] - The biotechnology sector accounts for over 35% of the total IPOs, emerging as the biggest winner in the market [3] Group 2 - Three main drivers are contributing to the market recovery: 1. The trend of Chinese companies returning to Hong Kong continues, with 28 companies completing secondary listings and over 4.2 trillion HKD in market value awaiting return [5] 2. The Hong Kong Stock Exchange's regulatory innovations have attracted 18 companies to apply for listing, with optimized entry requirements for biotech firms [5] 3. International capital is being reallocated, with net inflows from southbound funds exceeding 280 billion HKD over five months, and foreign institutional holdings rising to 63% [5] Group 3 - Key investment opportunities in the second half of 2023 include sectors such as hard technology (semiconductors, AI), new energy, biomedicine (gene therapy, medical devices), and new consumption (domestic brands, cross-border e-commerce) [7] - Notable companies expected to raise significant funds include Lens Technology (5 billion HKD) as a core supplier for Apple and Kangfang Biopharmaceuticals (3 billion HKD) with its first PD-1 dual antibody [7] Group 4 - Current market conditions present an optimal window for companies to list in Hong Kong, with valuation levels up 25% compared to 2024 and a 40% increase in international investment bank participation [8] - Companies planning to go public should expedite preparations to complete listings within the year, while investors are advised to focus on IPO projects with specific characteristics [10][11]

Global Market Dynamics - The US stock market showed strong performance with the S&P 500 and Nasdaq reaching new highs, driven by better-than-expected non-farm payroll data [3][10] - European markets also rose, with the UK leading gains amid reduced political uncertainty [10] - The A-share market in China saw an increase, particularly in sectors related to Apple and innovative pharmaceuticals [17] Trade and Economic Agreements - The US has reached a trade agreement with Vietnam, imposing a 20% tariff on Vietnamese exports and a 40% tariff on goods subject to "transshipment" from China, complicating China's trade through Vietnam [6] - The agreement emphasizes the importance of origin certification, which may impact China's ability to utilize Vietnam for trade [6] - The report suggests that Chinese companies may accelerate overseas expansion, creating a new cycle of local production and consumption [6] Employment and Economic Indicators - The US added 256,000 non-farm jobs in June, exceeding expectations, while the unemployment rate fell to 4.1% [9][10] - However, the report indicates underlying weaknesses in the job market, with a significant number of discouraged workers not counted in the labor force [9] - The report anticipates that the Federal Reserve may lower interest rates in September due to ongoing economic concerns [9] Sector Performance - In the Hong Kong market, large technology stocks faced declines, while healthcare and materials sectors showed strength [12][13] - Macau's gaming industry is projected to recover, with a forecasted GGR growth of 7.6% in 2025, driven by increased market share for major operators [15] - The report highlights the potential for growth in the submarine cable sector, driven by AI and increased demand for deep-sea technology [20] Fixed Income Market - US Treasury yields rose following strong non-farm payroll data, with the yield curve flattening as the market adjusts to reduced rate cut expectations [29][32] - The report notes a significant increase in the US national debt ceiling by $5 trillion, alleviating immediate default risks [32] - Asian investment-grade bonds remained stable, with slight narrowing of spreads observed [32]